Development and Analysis of Retroviral Vectors Expressing Human Factor VIII as a Potential Gene Therapy for Hemophilia A
- 1 November 1995
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 6 (11) , 1363-1377
- https://doi.org/10.1089/hum.1995.6.11-1363
Abstract
To develop a potential gene therapy strategy for the treatment of hemophilia A, we constructed several retroviral vectors expressing a B-domain-deleted factor VIII (FVIII) cDNA. We confirmed previous reports that when the FVIII cDNA is inserted into a retroviral vector, the vector mRNA is decreased resulting in significantly (100- to 1,000-fold) lower vector titers. In an attempt to overcome this inhibition we pursued two independent strategies. First, site-directed mutagenesis was employed to change the structure of a putative 1.2-kb FVIII RNA inhibitory sequence (INS). Second, the FVIII gene was transcribed from a retroviral vector containing a 5′ intron. Results demonstrated that the intron increased FVIII expression up to 20-fold and viral titer up to 40-fold but conservative mutagenesis of the putative FVIII INS region failed to yield a significant increase in FVIII expression or titer. Using the improved FVIII splicing vector, we transduced a variety of cell types and were able to demonstrate relatively high FVIII expression (10–60 ng of FVIII/106 cells/24 hr). These results underscore the usefulness of these transduced cell types for potential in vivo delivery of FVIII. Insertion of a human factor VIII cDNA into retroviral vectors results in a 100- to 1,000-fold decrease in vector titer and poor FVIII gene expression. Chuah et al. address this problem using two approaches: (i) conservative mutagenesis of a putative FVIII INS region and (ii) insertion of an intron 5′ to the FVIII cDNA. Results indicated that conservative mutagenesis of the FVIII INS region failed to increase FVIII expression and restore retroviral titer, but the inclusion of an intron in the retroviral backbone led to improved vector titer and FVIII gene expression. Using this improved FVIII retroviral vector, a variety of cell types were transduced, and relatively high FVIII expression levels were observed in cells of epithelial, endothelial, or fibroblastic origin.Keywords
This publication has 39 references indexed in Scilit:
- Targeted disruption of the mouse factor VIII gene produces a model of haemophilia ANature Genetics, 1995
- Sequences Within the Coding Regions of Clotting Factor VIII and CFTR Block Transcriptional ElongationHuman Gene Therapy, 1995
- Inhibition of Human Immunodeficiency Virus Type-1 by Retroviral Vectors Expressing Antisense-TARHuman Gene Therapy, 1994
- Gene therapy and the hemophiliasPublished by American Medical Association (AMA) ,1994
- Toward Gene Therapy for Hemophilia A: Long-Term Persistence of Factor VIII-Secreting Fibroblasts after Transplantation into Immunodeficient MiceHuman Gene Therapy, 1993
- Retrovirus-Mediated Gene Transfer into Canine Thyroid Using anEx VivoStrategyHuman Gene Therapy, 1993
- Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technologyAnnals of Hematology, 1991
- Synthetic oligonucleotide probes deduced from amino acid sequence dataJournal of Molecular Biology, 1985
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Rescue of a splicing defective mutant by insertion of an heterologous intronNature, 1980